Bleximenib Drug Study in Leukemia Patients
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a radioactive form of the drug bleximenib in people with acute leukemia that has come back or not responded to treatment. It looks for specific genetic changes in the leukemia cells and may help researchers understand how the drug works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You weigh at least 40 kilograms (about 88 pounds).
- Your leukemia has come back after treatment or not responded, and it has a certain gene change (KMT2A, NPM1, NUP98, or NUP214).
- You are able to take care of yourself and are up and about more than half of your waking hours.
- You have regular bowel movements (at least one bowel movement every two days).
- If you could become pregnant, you must have a negative pregnancy test before the first dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial adds an experimental drug called bleximenib to the usual chemotherapy for people newly diagnosed with AML who have certain genetic changes (NPM1 or KMT2A). The goal is to see if adding this drug helps the treatment work better.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
This Phase 1 trial tests MRX-2843 in teenagers and adults whose leukemia has come back or did not respond to prior treatment. The main goals are to find safe dosing and learn how the body processes the drug.
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
This Phase 1/2 trial tests bleximenib, a targeted medicine, for people whose acute leukemia has specific gene changes and has come back or does not respond to treatment. It may help by attacking these leukemia-specific targets when other treatment options have run out.
This Phase 1/2 study tests whether BLEX 404 taken by mouth, added to pemetrexed plus cisplatin chemotherapy, is safe and works better for certain people with newly diagnosed advanced lung cancer. It mainly looks for side effects first, and also checks tumor response.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.